Human IL-13 R alpha 1 Protein, His Tag (MALS & SPR verified)
分子別名(Synonym)
IL13RA1,CD213A1,IL-13Ra,NR4,RP13-128O4.2,IL13Rα1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-13 R alpha 1 Protein, His Tag (IL1-H5224) is expressed from human 293 cells (HEK293). It contains AA Gly 22 - Thr 343 (Accession # NP_001551.1).
Predicted N-terminus: Gly 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 37.7 kDa. The protein migrates as 45-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素13受體α1也被稱為IL13RA1、NR4和CD213A1(分化簇213A1)。IL13 Rα1 cDNA編碼一個427個氨基酸(aa)殘基的前體蛋白,具有一個推定的21個氨基酸殘基信號肽、一個324個氨基酸殘基胞外結(jié)構(gòu)域、一個23個氨基酸殘基數(shù)的跨膜區(qū)和一個59個氨基酸殘數(shù)的細(xì)胞質(zhì)尾部。人和小鼠IL13Rα1具有76%的氨基酸序列同一性。IL13RA1是白細(xì)胞介素13受體的一個亞基。該亞基與IL13和IL4受體共享的IL4受體α形成受體復(fù)合物。該亞基作為IL13受體的主要IL13結(jié)合亞基,也可能是IL4受體的組成部分。該蛋白已被證明與酪氨酸激酶TYK2結(jié)合,因此可能介導(dǎo)導(dǎo)致IL13和IL4誘導(dǎo)的JAK1、STAT3和STAT6激活的信號傳導(dǎo)過程。
關(guān)鍵字: IL13RA1;IL13RA1蛋白;IL-13 R alpha 1;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。